Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer

Medical Oncology

Volumn 27, Issue 4, 2010, Pages 1303-1308

  Qu, Yiqing ^a   Yang, Yie ^b   Liu, Baoyi ^a   Xiao, Wei ^a  

^a SHANDONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Gemcitabine; Non small cell lung cancer; Proteomics; Sorcin

Indexed keywords

BIOLOGICAL MARKER; GEMCITABINE; SORCIN;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; DNA FINGERPRINTING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; BLOTTING, WESTERN; CALCIUM-BINDING PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTEOMICS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SURVIVAL RATE; TANDEM MASS SPECTROMETRY; TUMOR CELLS, CULTURED;

EID: 79951768348     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9379-5     Document Type: Article

References (21)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin. 2002;52:23-47.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-8. (Pubitemid 34438899)
3. Danesi R, Altavilla G, Giovannetti E, Rosell R. Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. Pharmacogenomics. 2009;10:69-80. Review.
4. Sève P, Dumontet C. Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents. 2005;5:73-88. Review. (Pubitemid 40081296)
5. Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH, Yang PC. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer. 2008;59:105-10.
6. Akada M, Crnogorac-Jurcevic T, Lattimore S, Mahon P, Lopes R, Sunamura M, et al. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res. 2005;11:3094-101. (Pubitemid 40525216)
7. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Mikuria K, Fujimoto M, Maehara S, et al. Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol. 2007;31:1345-50.
8. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 2004;64:3761-6. (Pubitemid 38697284)
9. Li J, Steen H, Gygi SP. Protein profiling with cleavable isotopecoded affinity tag (cICAT) reagents: the yeast salinity stress response. Mol Cell Proteomics. 2003;2:1198-204.
10. Sethuraman M, McComb ME, Heibeck T, Costello CE, Cohen RA. Isotope-coded affinity tag approach to identify and quantify oxidant-sensitive protein thiols. Mol Cell Proteomics. 2004;3:273-8. (Pubitemid 38714283)
11. Rosell R, Taron M, Alberola V, Massuti B, Felip E. Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer. 2003;41: S97-102. (Pubitemid 36819001)
12. Oguri T, Achiwa H, Muramatsu H, Ozasa H, Sato S, Shimizu S, et al. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett. 2007;256:112-9. (Pubitemid 47333332)
13. Castagna A, Antonioli P, Astner H, Hamdan M, Righetti SC, Perego P, et al. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics. 2004;4:3246-67. (Pubitemid 39372405)
14. Liu Y, Liu H, Han B, Zhang JT. Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res. 2006;66:3248-55.
15. Yang YX, Chen ZC, Zhang GY, Yi H, Xiao ZQ. A subcellular proteomic investigation into vincristine-resistant gastric cancer cell line. J Cell Biochem. 2008;104:1010-21. (Pubitemid 351830847)
16. Pan S, Cheng L, White JT, Lu W, Utleg AG, Yan X, et al. Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. OMICS. 2009;13:345-54.
17. Keenan J, Murphy L, Henry M, Meleady P, Clynes M. Proteomic analysis of multidrug-resistance mechanisms in adriamycinresistant variants of DLKP, a squamous lung cancer cell line. Proteomics. 2009;9:1556-66.
18. Hasegawa N, Mizutani K, Suzuki T, Deguchi T, Nozawa Y. A comparative study of protein profiling by proteomic analysis in camptothecin-resistant PC3 and camptothecin-sensitive LNCaP human prostate cancer cells. Urol Int. 2006;77:347-54. (Pubitemid 44837005)
19. Qi J, Liu N, Zhou Y, Tan Y, Cheng Y, Yang C, et al. Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis. Biochem Biophys Res Commun. 2006;349:303-9. (Pubitemid 44348892)
20. Zhou Y, Xu Y, Tan Y, Qi J, Xiao Y, Yang C, et al. Sorcin, an important gene associated with multidrug-resistance in human leukemia cells. Leuk Res. 2006;30:469-76. (Pubitemid 43254968)
21. Kawakami M, Nakamura T, Okamura N, Komoto C, Markova S, Kobayashi H, et al. Knock-down of sorcin induces up-regulation of MDR1 in HeLa cells. Biol Pharm Bull. 2007;30:1065-73. (Pubitemid 46883867)